BRAFTOVI + MEKTOVI continued to show a substantial median overall survival benefit of 47.6 months in treatment-naïve patients with BRAF V600E-mutant metastatic non-small cell lung cancer after ...
The study also presented the first external validation and use in patients with early RA of six proposed screening strategies ...
Analysts note that the ILD Treatment Market is poised for significant expansion over the next decade, with a compound annual growth rate (CAGR) expected in the high single digits. While high treatment ...
Singing can improve the quality of life of people with lung disease and help reduce their symptoms, according to a gold-standard randomzed-controlled trial presented at the European Respiratory ...
Background Compared with cytotoxic chemotherapy, the efficacy and safety of immune checkpoint inhibitors (ICIs) for patients ...
An 82-year-old woman with a history of congestive heart failure was admitted to this hospital for volume overload. Ascites, ...
Please provide your email address to receive an email when new articles are posted on . “Prior studies in systemic sclerosis (SSc) have not evaluated the relationship between specific bacterial ...
Patients with rheumatoid arthritis-associated lung disease demonstrate a significant increased risk for serious infection vs.
Avascular areas on baseline nailfold capillaroscopy are strong, independent predictors of major cardiovascular events and all ...
UVA Health lung researchers are developing a promising approach to detecting patients at risk of interstitial lung disease (ILD), an increasingly common condition that is a leading reason for lung ...
The FDA approved nerandomilast (Jascayd) tablets for idiopathic pulmonary fibrosis (IPF), the first new product for the progressive lung condition in over a decade, the agency announced on Tuesday.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback